Highlights Roche Holding AG

Stocks

ROP

CH1499059983

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 07:45:58 17/07/2026 pm IST			5-day change	1st Jan Change
334.10 ^CHF	+0.75%		-0.59%	+1.95%

15/07	Berenberg Downgrades Qiagen Rating, Price Target Amid Rising Competition, Growth Concerns	MT
15/07	Roche's Gazyva/Gazyvaro Lands Priority Review From US FDA in Nephropathy	MT

Highlights

15/07	Roche's Gazyva/Gazyvaro Lands Priority Review From US FDA in Nephropathy	MT
15/07	Roche Announces FDA Grants Priority Review to Roche?s Gazyva/Gazyvaro for Adults with Primary Membranous Nephropathy	CI
14/07	Roche Introduces Cobas Hepatitis D Virus Test for Use on Cobas 5800/6800/8800 Systems	CI
09/07	Roche's Tuberculosis Test Receives CE Mark	MT
08/07	ABB Robotics Partners with Roche Diagnostics	MT
07/07	Roche Presents New Data in Alzheimer?S Disease Portfolio At Aaic 2026	CI
02/07	Roche Reports Positive Results from Phase Iii Krascendo 1 Study Evaluating Divarasib Against Approved Kras G12c Inhibitors in Previously Treated Kras G12c Non-Small Cell Lung Cancer	CI
30/06	Roche Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Enspryng for Thyroid Eye Disease	CI
30/06	Roche Receives US Priority Review Status for Thyroid Eye Disease Treatment	MT
29/06	Excalipoint Therapeutics And Roches Announce Clinical Trial Collaboration To Evaluate EXP011 In DLL3-Expressing Solid Tumors	CI
29/06	Roche Announces Launch Of AXELIOS 1 Sequencing Platform	CI
29/06	Switzerland's Roche Introduces New Sequencing Platform	MT
25/06	Roche Holding AG Announces FDA Grants Priority Review Status to its Atezolizumab for Treatment of Certain Type of Stage III Colorectal Cancer	CI
18/06	Roche Receives FDA Acceptance for Supplemental Biologics License Application For Lunsumio And Polivy Combination For Relapsed Or Refractory Large B-Cell Lymphoma	CI
18/06	Roche Wins US FDA Nod for Lymphoma Drug Combo	MT
18/06	FDA approves first generic version of Roche's flu drug	RE
13/06	Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living with Prostate Cancer	CI
11/06	Roche Announces FDA Grants Priority Review For Roche's Tecentriq For A Certain Type Of Stage III Colon Cancer	CI
11/06	Roche's Tecentriq, Chemotherapy Combo Gets US FDA Priority Review for Colon Cancer	MT
11/06	Roche Announces IVDR Approval For VENTANA MMR RxDx Panel Companion Diagnostic Across Multiple Cancer Types And Therapies	CI
08/06	Roche Holding AG And Nurix Therapeutics, Inc. Announce Global Collaboration To Co-Develop And Co-Commercialise Potential Best-In-Class BTK Degrader Bexobrutideg Across Malignant Haematology, Immunology And Neurology	CI
08/06	Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics	RE
08/06	Roche enters $2 billion cancer drug agreement with Nurix Therapeutics	RE
08/06	Roche, Nurix Therapeutics to Develop, Commercialize BTK Degrader Bexobrutideg	MT
06/06	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE